摘要
目的 观察不同年龄、性别、病理类型、手术方式、术后13 1I治疗时间、13 1I剂量、TSH水平以及剩余甲状腺外转移灶是否同时摄碘等因素对分化型甲状腺癌术后患者首次13 1I清除剩余甲状腺的影响。方法 分化型甲状腺癌术后患者 85例 ,手术治疗后 ,口服13 1I 1.11～ 5 .5 5GBq进行首次13 1I治疗 ,3～ 6个月后随访 ,以颈部剩余甲状腺显像与周围本底相比未见摄碘为成功清除的标准。结果85例中成功者 5 8例 ,成功率 6 8.2 %。不同的13 1I剂量、手术方式、术后首次治疗时间、TSH水平的变化以及剩余甲状腺外转移灶是否同时摄碘分别与成功率有一定关系 ;其中术后首次治疗时间与成功率之间呈负相关 (r=- 1.10 84,r0 .0 1( 3 ) =0 .95 9,P <0 .0 1)。不同年龄、性别及病理类型与成功率之间无明显关系。结论 适当的13 1I剂量、甲状腺全切手术、术后首次13 1I治疗时间 3个月以内、5 0mU/L以上的TSH水平以及仅有剩余甲状腺摄碘的分化型甲状腺癌术后患者疗效较好。疗效与患者的年龄。
Objective To study the influence of age, sex, type of surgery, pathologic type of the tumor, postoperative time to the administration and the dose of radioiodine , TSH level and the existence of radioiodine uptake beyond thyroid to first radioiodine ablation of residual thyroid tissue (RTT) in well-differentiated thyroid cancer after surgery.Methods Eighty-five well-differentiated thyroid cancer patients after surgery were ablated of RTT with radioiodine from 1975 to 1998 and were followed up for 3～6 months after ablation. Using the absence of visible uptake compared with background as the criterion for successful ablation. Results Fifty-eight of 85 patients (68.2%) had successful ablation of RTT after the first administration of radioiodine. The results were statistically related to the type of surgery, the time after surgery to the ablation and the dosage of radioiodine, TSH level and the simultaneous existence of radioiodine uptake in metastatic site in the patients gained successfully ablation (P<0.05); there were no statistically significant relation with age, sex and pathologic type of tumor.Conclusions In well-differentiated thyroid cancer, there would be better effect of first ablation of RTT with suitable dosage of radioiodine, total thyroidectomy, above 50 mU/L TSH level,ablation conducted within 3 months after surgery and radioiodine uptake found only in RTT. The effectiveness of first ablation of RTT possesses no relationship with the age, sex and the pathologic type of the tumor.
出处
《中华核医学杂志》
CAS
CSCD
北大核心
2001年第2期91-92,共2页
Chinese Journal of Nuclear Medicine
